

## CombiGene has concluded a successful learning and memory study in the CG01 epilepsy project.

CombiGene has recently concluded a successful learning and memory study in the CG01 epilepsy project. The outcome of the study is very gratifying and shows that NPY and Y2, the active substances in CG01, have no significant negative effect on cognitive functions.

### **No negative effect on cognitive function**

NPY, one of the active substances in CG01, is associated with several physiological processes in the body, among others, memory and learning. CombiGene has therefore received an inquiry from the FDA and the Swedish Medical Products Agency as to whether CG01 has any impact on cognitive functions. The concluded learning and memory study answers that important question: increased expression of NPY and Y2 has no negative effect on memory or learning functions in the experimental model used in the study.

David Woldbye, one of CombiGene's scientific founders, commented on the results of the study. "The results of earlier academic studies on the effect of NPY on memory and learning have been contradictory. It is therefore especially pleasing to note that we can now demonstrate that we do not affect memory and learning when we inject CG01 into one of the brain's two hippocampi, precisely as we intend to do in humans."



*David Woldbye  
Scientific founder*

## PRESS RELEASE

Lund, March 24 2020



Karin Agerman, CombiGene's Chief Research and Development Officer, is also very satisfied with the outcomes of this study and the recently published pharmacokinetic study. "With the completion of the memory study it is very reassuring to have successfully answered several questions from the FDA and the Swedish Medical Products Agency. This brings us one step closer to start the first study in humans. More and more pieces in the CG01 project are now falling into place."



Karin Agerman  
Chief Research and Development Officer

---

## About CombiGene AB

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 0399, [info@fnca.se](mailto:info@fnca.se).

## For further information:

CombiGene AB (publ)  
Jan Nilsson, CEO  
Phone: +46 (0)704 66 31 63  
[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Arne Ferstad, Chairman of the board  
Phone: +44 (0)749 652 61 42  
[arne.ferstad@combigene.com](mailto:arne.ferstad@combigene.com)

**Please read MORE FROM THE COMPANY, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and press releases are available at [www.combigene.com](http://www.combigene.com)**



CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

[www.combigene.com](http://www.combigene.com)

CombiGene AB (publ) Medicin Village, SE-223 81 Lund, Sweden  
[info@combigene.com](mailto:info@combigene.com)